Compare Adaptive Biotechnologies Corp (ADPT) vs Enovix Corporation (ENVX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Enovix Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Enovix Corporation trades at $4.98 (market cap $1.09B). The key difference: Adaptive Biotechnologies Corp is far larger — about 3.1× Enovix Corporation's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ADPT | ENVX | |
|---|---|---|
Market Cap | $3.33B | $1.09B |
Sector | Health | Technology |
52-Week High | $22.37 | $15.93 |
52-Week Low | $10.24 | $4.84 |
Enterprise Value | $3.19B | $1.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ENVX trades at $5.62, up 4.85% today, but technical indicators signal a bearish trend with support at $5 and resistance at $6. The company reported Q1 2026 revenue above guidance and an EPS beat, yet remains unprofitable with a net margin of -499.64%. Analyst consensus is bullish with a $12.75 price target, driven by growth in silicon-anode batteries for AI devices, smart eyewear, and defense markets.
The stock offers high-risk, high-reward potential given its speculative growth story versus persistent losses. Key catalysts include scaling commercial production and smartphone qualification, but execution risks and cash burn require careful monitoring. Investors should weigh analyst optimism against fundamental challenges in the competitive battery sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
